Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
Fig 1
Cumulative risk (grade 3–5 serious adverse events [G3-5 AEs], in red) and benefit (overall response rate, in black) trends for sorafenib monotherapy.
(A) Phase I, (B) Phase II, and (C) Phase III trials, ordered by enrolment date. Per-trial data are available in our supplementary materials (see S1 Data).
doi: https://doi.org/10.1371/journal.pbio.2000487.g001